These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18379834)

  • 1. Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis.
    Perry ME; Stirling A; Hunter JA
    Clin Rheumatol; 2008 Jul; 27(7):923-5. PubMed ID: 18379834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis.
    Nakamura T; Higashi S; Tomoda K; Tsukano M; Shono M
    Clin Rheumatol; 2010 Dec; 29(12):1395-401. PubMed ID: 20440529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis.
    Smith GR; Tymms KE; Falk M
    Intern Med J; 2004; 34(9-10):570-2. PubMed ID: 15482271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis.
    Nakamura T; Higashi S; Tomoda K; Tsukano M; Baba S
    Clin Exp Rheumatol; 2007; 25(4):518-22. PubMed ID: 17888205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis.
    Nakamura T
    Mod Rheumatol; 2008; 18(2):109-18. PubMed ID: 18369528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of etanercept vs cyclophosphamide as treatment for patients with amyloid A amyloidosis secondary to rheumatoid arthritis.
    Nakamura T; Higashi S; Tomoda K; Tsukano M; Shono M
    Rheumatology (Oxford); 2012 Nov; 51(11):2064-9. PubMed ID: 22879465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome.
    Drewe E; Huggins ML; Morgan AG; Cassidy MJ; Powell RJ
    Rheumatology (Oxford); 2004 Nov; 43(11):1405-8. PubMed ID: 15316120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Response to anti-TNF-alpha treatment for secondary renal amyloidosis in a patient with ankylosing spondylitis].
    Bellissimo S; Ferrucci MG; Gallo A; Stisi S
    Reumatismo; 2007; 59(3):240-3. PubMed ID: 17898885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of amyloidosis in patients with rheumatoid arthritis under TNF-blocking agents.
    Roque R; Ramiro S; Cordeiro A; Gonçalves P; Da Canas S; Santos MJ
    Clin Rheumatol; 2011 Jun; 30(6):869-70. PubMed ID: 21484228
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy.
    Gottenberg JE; Merle-Vincent F; Bentaberry F; Allanore Y; Berenbaum F; Fautrel B; Combe B; Durbach A; Sibilia J; Dougados M; Mariette X
    Arthritis Rheum; 2003 Jul; 48(7):2019-24. PubMed ID: 12847696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case with rheumatoid arthritis and systemic reactive AA amyloidosis showing rapid regression of amyloid deposition on gastroduodenal mucosa after a combined therapy of corticosteroid and etanercept.
    Ishii W; Kishida D; Suzuki A; Shimojima Y; Matsuda M; Hoshii Y; Ikeda S
    Rheumatol Int; 2011 Feb; 31(2):247-50. PubMed ID: 19820941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective anti-TNF-alpha therapy can induce rapid resolution and sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis.
    Kuroda T; Wada Y; Kobayashi D; Murakami S; Sakai T; Hirose S; Tanabe N; Saeki T; Nakano M; Narita I
    J Rheumatol; 2009 Nov; 36(11):2409-15. PubMed ID: 19797512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients.
    Kobak S; Oksel F; Kabasakal Y; Doganavsargil E
    Clin Rheumatol; 2007 Dec; 26(12):2191-2194. PubMed ID: 17611708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein.
    Gillmore JD; Lovat LB; Persey MR; Pepys MB; Hawkins PN
    Lancet; 2001 Jul; 358(9275):24-9. PubMed ID: 11454373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No regression of renal amyloid mass despite remission of nephrotic syndrome in a patient with TRAPS following etanercept therapy.
    Simsek I; Kaya A; Erdem H; Pay S; Yenicesu M; Dinc A
    J Nephrol; 2010; 23(1):119-23. PubMed ID: 20091495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-TNF therapy in renal amyloidosis in refractory rheumatoid arthritis: a new therapeutic perspective.
    Nobre CA; Callado MR; Rodrigues CE; de Menezes DB; Vieira WP
    Rev Bras Reumatol; 2010; 50(2):205-10. PubMed ID: 21125155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of etanercept on a case of amyloidosis secondary to ankylosing spondylitis: results of 2-year follow-up.
    Yilmaz H; Kocabas H; Erkin G
    Acta Reumatol Port; 2013; 38(4):299-301. PubMed ID: 24435036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history and outcome in systemic AA amyloidosis.
    Lachmann HJ; Goodman HJ; Gilbertson JA; Gallimore JR; Sabin CA; Gillmore JD; Hawkins PN
    N Engl J Med; 2007 Jun; 356(23):2361-71. PubMed ID: 17554117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A review for recent advances in AA amyloid research and therapeutic approach to AA amyloidosis complicating rheumatoid arthritis].
    Tamura H; Hasegawa K
    Nihon Rinsho Meneki Gakkai Kaishi; 2009 Feb; 32(1):35-42. PubMed ID: 19252376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature.
    Lane T; Gillmore JD; Wechalekar AD; Hawkins PN; Lachmann HJ
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S46-53. PubMed ID: 26120866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.